Qin Li-sen, Jia Pi-feng, Zhang Zhi-qing, Zhang Shi-ming
Department of Neurosurgery, the First Affiliated Hospital of Soochow University, No. 188, Shi-zi Street, Suzhou, Jiangsu, People's Republic of China.
Department of Neurosurgery, the Sixth People's Hospital of Yancheng, Yan-cheng, Jiangsu, People's Republic of China.
J Exp Clin Cancer Res. 2015 May 30;34(1):57. doi: 10.1186/s13046-015-0174-1.
BACKGROUND: The primary glioblastoma multiforme (GBM) is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months. The search for novel and more efficient chemo-agents against this disease is urgent. Salinomycin induces broad anti-cancer effects; however, its role in GBM and the underlying mechanism are not clear. RESULTS: Here we found that salinomycin induced both apoptosis and necrosis in cultured glioma cells, and necrosis played a major role in contributing salinomycin's cytotoxicity. Salinomycin induced p53 translocation to mitochondria, where it formed a complex with cyclophilin-D (CyPD). This complexation was required for mitochondrial permeability transition pore (mPTP) opening and subsequent programmed necrosis. Blockade of Cyp-D by siRNA-mediated depletion or pharmacological inhibitors (cyclosporin A and sanglifehrin A) significantly suppressed salinomycin-induced glioma cell necrosis. Meanwhile, p53 stable knockdown alleviated salinomycin-induced necrosis in glioma cells. Reactive oxygen species (ROS) production was required for salinomycin-induced p53 mitochondrial translocation, mPTP opening and necrosis, and anti-oxidants n-acetylcysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) inhibited p53 translocation, mPTP opening and glioma cell death. CONCLUSIONS: Thus, salinomycin mainly induces programmed necrosis in cultured glioma cells.
J Exp Clin Cancer Res. 2015-5-30
Biochem Biophys Res Commun. 2014-6-16
Biochem Biophys Res Commun. 2013-7-8
Biochem Biophys Res Commun. 2015-8-14
Int J Mol Sci. 2025-7-9
Mater Today Bio. 2025-3-17
Nat Rev Mol Cell Biol. 2025-4-9
Front Immunol. 2023
Cell Death Dis. 2023-10-25
Front Immunol. 2022
Int J Mol Sci. 2022-8-19
J Exp Clin Cancer Res. 2014-6-11
Biochem Biophys Res Commun. 2014-4-13
CA Cancer J Clin. 2014-1-7
Curr Med Chem. 2013